Conferences - Results from #240

Viewing 241-260 of 11869 articles

ESMO 2024: Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE

ESMO 2024: Invited Discussant: CONTACT-02 Study and STAMPEDE Docetaxel Trials

ESMO 2024: Cabozantinib plus Atezolizumab versus 2nd Novel Hormonal Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Results of the Phase III, Randomized, CONTACT-02 Study

ESMO 2024: Decipher® mRNA Score for Prediction of Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy for Advanced Prostate Cancer: An Ancillary Study of the STAMPEDE Docetaxel Trials

ESMO 2024: Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: Conditional Survival and Long-Term Safety in Patients Treated for ≥1 or ≥2 Years in JAVELIN Bladder 100

New Data from TAR-200 Phase 2b SunRISe-1 Study Show 84 Percent Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer

ESMO 2024: Invited Discussant: A Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA)

ESMO 2024: TAR-200 +/- Cetrelimab and Cetrelimab Alone in Patients with BCG-Unresponsive High-Risk NMIBC: Updated Results from SunRISe-1

ESMO 2024: Invited Discussant: Futibatinib Plus Pembrolizumab, Retrospective Assessment of Nectin-4 Expression, and Disitamab Vedotin

ESMO 2024: Fecal Microbiota Transplantation vs Placebo in Patients Receiving Pembrolizumab plus Axitinib for Metastatic Renal Cell Carcinoma. Preliminary Results of the Randomized Phase 2 TACITO Trial.

ESMO 2024: Pre-Treatment Risk Factors for Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients with Advanced Urothelial Carcinoma: Analysis of UNITE

ESMO 2024: Invited Discussant: Efficacy of SPLASH and UpFrontPSMA Trials

ESMO 2024: Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA)

ESMO 2024: Novel Serum Glycoproteomic Biomarkers Predict Response to Nivolumab plus Cabozantinib Versus Sunitinib in Advanced RCC: Analysis from CheckMate 9ER

ESMO 2024: Phase 2 Study of Futibatinib plus Pembrolizumab in Patients with Advanced/Metastatic Urothelial Carcinoma: Final Analysis of Efficacy and Safety

ESMO 2024: Preliminary Efficacy And Safety Of Disitamab Vedotin With Pembrolizumab In Treatment-Naive HER2-Expressing, Locally Advanced Or Metastatic Urothelial Carcinoma: RC48G001 Cohort C

ESMO 2024: UpFrontPSMA : A Randomized Phase II Study of Sequential 177Lu-PSMA-617 and Docetaxel versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor (SPLASH)

ESMO 2024: Radioligand Theranostics in Prostate Cancer: Status Quo and New Developments

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

8
9
10
11
12
13
14
15
16
17